Marzo AL - Search Results

1

Tumor antigens are constitutively presented in the draining lymph nodes.

Marzo AL, Lake RA, Lo D, Sherman L, McWilliam A, Nelson D, Robinson BW, Scott B. Marzo AL, et al. J Immunol. 1999 May 15;162(10):5838-45. J Immunol. 1999. PMID: 10229818

2

T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors.

Marzo AL, Lake RA, Robinson BW, Scott B. Marzo AL, et al. Cancer Res. 1999 Mar 1;59(5):1071-9. Cancer Res. 1999. PMID: 10070965

3

Cross-presentation of tumour antigens: evaluation of threshold, duration, distribution and regulation.

Robinson BW, Lake RA, Nelson DJ, Scott BA, Marzo AL. Robinson BW, et al. Among authors: marzo al. Immunol Cell Biol. 1999 Dec;77(6):552-8. doi: 10.1046/j.1440-1711.1999.00876.x. Immunol Cell Biol. 1999. PMID: 10571677 Review.

4

Tumor-specific CD4+ T cells have a major "post-licensing" role in CTL mediated anti-tumor immunity.

Marzo AL, Kinnear BF, Lake RA, Frelinger JJ, Collins EJ, Robinson BW, Scott B. Marzo AL, et al. J Immunol. 2000 Dec 1;165(11):6047-55. doi: 10.4049/jimmunol.165.11.6047. J Immunol. 2000. PMID: 11086036

5

Lack of ignorance to tumor antigens: evaluation using nominal antigen transfection and T-cell receptor transgenic lymphocytes in Lyons-Parish analysis--implications for tumor tolerance.

Robinson BW, Scott BM, Lake RA, Stumbles PA, Nelson DJ, Fisher S, Marzo AL. Robinson BW, et al. Among authors: marzo al. Clin Cancer Res. 2001 Mar;7(3 Suppl):811s-817s. Clin Cancer Res. 2001. PMID: 11300477

6

Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells.

Nowak AK, Lake RA, Marzo AL, Scott B, Heath WR, Collins EJ, Frelinger JA, Robinson BW. Nowak AK, et al. Among authors: marzo al. J Immunol. 2003 May 15;170(10):4905-13. doi: 10.4049/jimmunol.170.10.4905. J Immunol. 2003. PMID: 12734333

7

Antisense oligonucleotides specific for transforming growth factor beta2 inhibit the growth of malignant mesothelioma both in vitro and in vivo.

Marzo AL, Fitzpatrick DR, Robinson BW, Scott B. Marzo AL, et al. Cancer Res. 1997 Aug 1;57(15):3200-7. Cancer Res. 1997. PMID: 9242450

8

Interleukin-6 involvement in mesothelioma pathobiology: inhibition by interferon alpha immunotherapy.

Bielefeldt-Ohmann H, Marzo AL, Himbeck RP, Jarnicki AG, Robinson BW, Fitzpatrick DR. Bielefeldt-Ohmann H, et al. Among authors: marzo al. Cancer Immunol Immunother. 1995 Apr;40(4):241-50. doi: 10.1007/BF01519898. Cancer Immunol Immunother. 1995. PMID: 7750122 Free PMC article.

9

Potential for interferon-alpha-based therapy in mesothelioma: assessment in a murine model.

Bielefeldt-Ohmann H, Fitzpatrick DR, Marzo AL, Jarnicki AG, Musk AW, Robinson BW. Bielefeldt-Ohmann H, et al. Among authors: marzo al. J Interferon Cytokine Res. 1995 Mar;15(3):213-23. doi: 10.1089/jir.1995.15.213. J Interferon Cytokine Res. 1995. PMID: 7584666

10

Transforming growth factor-beta: antisense RNA-mediated inhibition affects anchorage-independent growth, tumorigenicity and tumor-infiltrating T-cells in malignant mesothelioma.

Fitzpatrick DR, Bielefeldt-Ohmann H, Himbeck RP, Jarnicki AG, Marzo AL, Robinson BW. Fitzpatrick DR, et al. Among authors: marzo al. Growth Factors. 1994;11(1):29-44. doi: 10.3109/08977199409015049. Growth Factors. 1994. PMID: 7833058

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

45 results

Search Page

Filters